RxDoctor Payments DataLook up a doctor →

Sharon Upton

Acute Care · Oxford, MSNPI 1851408744

Payments from drug & device makers

$9,940in general payments, 2019–2025

Across 684 payments — averaging $14.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$942
  • Novo Nordisk$930
  • Boehringer Ingelheim$773
  • Bayer$721
  • Pfizer$663
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$9,85099%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,940 in reported general payments places this provider in the 95th percentile of 223 acute care providers in Mississippi.

See all acute care providers in Mississippi

Medicare billing

Part B allowed, 2024
$406,418
Medicare patients
838
Services billed
20,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$89,865
EliquisApixaban87$53,040
JardianceEmpagliflozin53$46,317
FarxigaDapagliflozin Propanediol30$23,585
Janumet XrSitagliptin Phos/Metformin Hcl29$19,691
MyrbetriqMirabegron22$14,411
Synjardy XrEmpagliflozin/Metformin Hcl18$12,850
QuliptaAtogepant11$11,301
JanumetSitagliptin Phos/Metformin Hcl14$10,492
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,914
Gabapentin251$4,287
Rosuvastatin Calcium422$4,239
Nebivolol Hcl37$3,051
Dexlansoprazole DrDexlansoprazole22$2,939
SynthroidLevothyroxine Sodium41$2,816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$930$89,86598 claims
Boehringer IngelheimJardiance, Synjardy Xr$773$59,16671 claims
PfizerEliquis$663$53,04087 claims
AstraZenecaFarxiga, Breztri Aerosphere$468$30,49941 claims
MerckJanumet Xr, Janumet$89$30,18343 claims
Astellas Pharma US IncMyrbetriq$270$14,41122 claims
AbbVieQulipta, Synthroid$1,422$14,11652 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 acute care providers in Mississippi.

Other acute care in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →